Stevanato Group (STVN) just posted its third quarter 2026 earnings, reporting sales of €326.1 million and net income of €41.8 million. These results give investors fresh numbers to reassess the stock. Despite the solid Q3 report and the Aptar Pharma collaboration announced in late October, Stevanato Group’s recent trading tells a different story. The share price is down about 30% over the past month and the 1-year total shareholder return has declined about 43%, pointing to fading momentum as...
Stevanato Group SpA (STVN) delivered solid Q3 2026 organic growth and margin expansion while flagging a temporary, single-customer GLP-1 volume decline expected to moderate 2027 growth.
Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.
Detailed price information for Stevanato Group S.P.A. (STVN-N) from The Globe and Mail including charting and trades.
Detailed price information for Stevanato Group S.P.A. (STVN-N) from The Globe and Mail including charting and trades.
Stevanato Group SpA (STVN) has an average rating of overweight and mean price target of $25.16, acco
PIOMBINO DESE, Italy, September 08, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences:
On August 4, Stevanato Group (NYSE:STVN) reported second-quarter revenue of €302.0 million, up 8% year over year, while also closing the sale of its California-based subsidiary, Balda C. Brewer Inc. The results paired steady growth in the company’s core drug containment and delivery business with a portfolio move that reshaped its bottom line for the […]
Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]
Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform. Learn why STVN stock is a buy.
Detailed price information for Stevanato Group S.P.A. (STVN-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.